ANN ARBOR, Mich., March 28, 2011 /PRNewswire/ — Adeona
Pharmaceuticals, Inc. (AMEX:
AEN), a developer of innovative medicines for serious central
nervous system diseases, announced today that the ongoing clinical
trial of its Trimesta™ (oral estriol) drug candidate has
received an additional $409,426 in grant funding from the National
Multiple Sclerosis Society (NMSS). The clinical trial is led by,
Rhonda Voskuhl, M.D., Director, University of California Los
Angeles (UCLA) Multiple Sclerosis Program, UCLA Department of
Neurology. Adeona also announced that as of March 1, 2011, the
clinical trial evaluating the reduction in the rate of relapses in
female multiple sclerosis (MS) patients is 85% enrolled.
“We are very grateful to the NMSS for its continuous support of
this MS program, from the preclinical development to the pilot and
multi-center clinical trials, and now this current grant funding,”
said Dr. Voskuhl. “Their commitment to pursuing estriol for MS
could potentially lead to a new, safe and effective oral therapy
for this debilitating disease.”
This ongoing clinical trial previously received a $5 million
grant from the NMSS in partnership with the NMSS’s Southern
California chapter, with support from the National Institutes of
Health, and $860,440 in grant funding through the American Recovery
and Reinvestment Act. In November 2010, Adeona announced that it
was awarded $244,480 under the Qualifying Therapeutic Discovery
Project Program to support research and development expenses
related to the Company’s MS program.
The 150-patient, randomized, double-blind, placebo-controlled
clinical trial of Trimesta is currently underway at 15 centers in
the United States. Investigators are administering either Trimesta
or matching placebo along with glatimer acetate (Copaxone®), an
FDA-approved therapy for MS, to women between the ages of 18-50 who
have
‘/>”/>
SOURCE
